
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is on track to achieve significant growth in the coming years due to the successful development and commercialization of Pylarify, a PSMA imaging agent for prostate cancer, as well as a robust portfolio of precision diagnostics including DEFINITY and Neuraceq. Additionally, their Alzheimer's diagnostic pipeline, including the recently approved MK6240, has the potential to significantly increase their market share in the future. Risks to the company's outlook include pricing challenges and potential delays in securing TPT status for their products, as well as potential operational and execution shortfalls following recent leadership changes and a pending CEO transition. Overall, LNTH's strong financial performance and strategic initiatives position it as an attractive investment opportunity in the competitive field of radiopharmaceuticals.
Bears say
Lantheus Holdings is projected to have a higher 2027 EPS, but is currently trading at a lower P/E ratio compared to its peers. With a potential re-acceleration in revenue and EPS growth in 2027, the company's multiple could increase and close the gap with its peers. Additionally, the company's gross profit has remained relatively stable, with recent divestitures and product volumes offsetting a decrease in net price. However, there may be potential margin dilution in the near-term due to new manufacturing facilities and product pricing.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares